Wuxi Apptec
Wuxi Apptec is recorded as a service provider in 35 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 35 trials · Latest update first
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)
Sponsor Bristol Myers Squibb International Corporation
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- Enrollment to the nivolumab plus relatlimab 960 mg group was stopped on 19 July 2021 after two participants in that group died, to protect participant safety.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl‑2 Inhibitor BGB‑11417 in Patients With Myeloid Malignancies
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody Drug Conjugate (ADC), Compared to Investigator’s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer
Sponsor Zai Lab (US) LLC
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Randomized, Open-Label, Blinded Endpoint Evaluation, Active-Controlled Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing Elective Primary Unilateral Total Knee Arthroplasty.
Sponsor Sirius Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/LY3650150 in Participants with Chronic Rhinosinusitis with Nasal Polyps on Background Intranasal Corticosteroids
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A phase Ib/II, multicenter study of the combination of LEE011 and BYL719 with letrozole in adult patients with advanced ER+ breast cancer
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Full title of the clinical trial: A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults with Active Sjögren’s Syndrome (POETYK SjS-1)
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected Tyrosine Kinase Inhibitor (TKI) in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multi-Center, Open Label Extension Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)
Sponsor Ns Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)
Sponsor Shanghai Henlius Biotech Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Bcl 2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Wuxi Apptec?
The 2026-10-09 snapshot links Wuxi Apptec to 35 distinct CTIS trials. Recorded services include Laboratory services, Serum PK and serum immunogenicity analysis, PK Sampling, ACZ885 pharmacokinetic, pharmacodynamic, immunogenicity analysis (China only), among 13 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Wuxi Apptec?
The most frequently recorded therapeutic areas are Haematological Malignancies, Solid Tumor Oncology, Immunology, Respiratory. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Wuxi Apptec conducted?
The linked trials record locations in 23 countries, including Spain, Italy, Germany, France, Poland. These are trial locations, not confirmed office locations or countries where Wuxi Apptec delivered services.
What can this page tell me about Wuxi Apptec's trial experience?
Browse 35 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Wuxi Apptec. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- WuXi AppTec GmbH
- Wuxi Apptec Co. Ltd.